DiaMedica Therapeutics to Attend the 13th Annual Craig-Hallum Alpha Select Conference November 17, 2022

Rhea-AI Summary

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, announced that President and CEO Rick Pauls will participate in the 13th Annual Craig-Hallum Alpha Select Conference on November 17, 2022, in New York. The conference presents an opportunity for investors to schedule meetings with DiaMedica’s management through their Craig-Hallum representative. DiaMedica focuses on developing innovative treatments for neurological disorders and kidney diseases, with its lead candidate DM199 targeting acute ischemic stroke and chronic kidney disease.

MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls, its President and CEO will be participating in the 13th Annual Craig-Hallum Alpha Select Conference being held in New York on Thursday, November 17, 2022.

Investors and attendees that would like to schedule a meeting with DiaMedica’s management can contact their Craig-Hallum representative to arrange a meeting.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality for the treatment of acute ischemic stroke and chronic kidney disease. For more information visit the Company’s website at www.diamedica.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221107005660/en/

Scott Kellen

Chief Financial Officer

Phone: (763) 496-5118

skellen@diamedica.com

Paul Papi

Corporate Communications

Phone: 617-899-5941

ppapi@diamedica.com

Source: DiaMedica Therapeutics Inc.

FAQ

What is DiaMedica Therapeutics participating in on November 17, 2022?

DiaMedica Therapeutics Inc. is participating in the 13th Annual Craig-Hallum Alpha Select Conference in New York.

Who will represent DiaMedica at the Craig-Hallum Conference?

Rick Pauls, the President and CEO of DiaMedica Therapeutics, will represent the company at the conference.

What is DM199, the lead candidate of DiaMedica?

DM199 is a recombinant form of the KLK1 protein aimed at treating acute ischemic stroke and chronic kidney disease.

How can investors schedule a meeting with DiaMedica's management during the conference?

Investors can contact their Craig-Hallum representative to arrange a meeting with DiaMedica’s management.

What is DiaMedica Therapeutics focused on developing?

DiaMedica Therapeutics is focused on developing novel treatments for neurological disorders and kidney diseases.